IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Cambrex Buys Estonian Firm

12:27 PM MST | January 21, 2008 | Alex Scott

Cambrex says that its Cambrex Karlskoga (Karlskoga, Sweden) subsidiary has agreed to acquire privately owned active pharmaceutical ingredients (API) R&D company ProSyntest (Tallinn, Estonia). Financial terms were not disclosed. ProSyntest, spun out of Tallinn University of Technology (Tallinn) in 1990, employs 25 chemists. The company’s activities include process development, and expertise in chiral chemistries. The acquisition “will enable Cambrex to more effectively compete in the high-growth, early clinical-stage pharmaceutical custom...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa